TY - JOUR
T1 - Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors
T2 - A meta-analysis
AU - Yanagisawa, Takafumi
AU - Mori, Keiichiro
AU - Katayama, Satoshi
AU - Mostafaei, Hadi
AU - Quhal, Fahad
AU - Laukhtina, Ekaterina
AU - Rajwa, Pawel
AU - Motlagh, Reza S.
AU - Aydh, Abdulmajeed
AU - König, Frederik
AU - Grossmann, Nico C.
AU - Pradere, Benjamin
AU - Miki, Jun
AU - Schmidinger, Manuela
AU - Egawa, Shin
AU - Shariat, Shahrokh F.
N1 - Publisher Copyright:
© 2022 Future Medicine Ltd.
PY - 2022/6
Y1 - 2022/6
N2 - Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Methods: PubMed, Web of Science and Scopus databases were searched for articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results: Fifteen studies comprising 1530 patients were eligible for meta-analysis. High levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein and lactate dehydrogenase were significantly associated with worse progression-free survival. High NLR and PLR were significantly associated with worse overall survival. Conclusion: High pretreatment NLR and PLR appear to be hematological prognostic factors of progression and overall mortality in mRCC patients treated with ICIs. These findings might help in the design of correlative biomarker studies to guide the clinical decision-making in the immune checkpoint inhibitor era. Plain language summary Identifying the predictive/prognostic factors that can be applied to daily clinical practice is mandatory to facilitate the use of immune checkpoint inhibitors. Some pretreatment hematological markers used in daily clinical practice appear to be prognostic factors in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors. We believe that the findings of the present meta-analysis might help researchers to design prospective correlative biomarker studies to guide clinical decision-making in the immunotherapy era.
AB - Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Methods: PubMed, Web of Science and Scopus databases were searched for articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results: Fifteen studies comprising 1530 patients were eligible for meta-analysis. High levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein and lactate dehydrogenase were significantly associated with worse progression-free survival. High NLR and PLR were significantly associated with worse overall survival. Conclusion: High pretreatment NLR and PLR appear to be hematological prognostic factors of progression and overall mortality in mRCC patients treated with ICIs. These findings might help in the design of correlative biomarker studies to guide the clinical decision-making in the immune checkpoint inhibitor era. Plain language summary Identifying the predictive/prognostic factors that can be applied to daily clinical practice is mandatory to facilitate the use of immune checkpoint inhibitors. Some pretreatment hematological markers used in daily clinical practice appear to be prognostic factors in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors. We believe that the findings of the present meta-analysis might help researchers to design prospective correlative biomarker studies to guide clinical decision-making in the immunotherapy era.
KW - C-reactive protein
KW - immune checkpoint inhibitor
KW - lactate dehydrogenase
KW - meta-analysis
KW - metastatic renal cell carcinoma
KW - neutrophil-to-lymphocyte ratio
KW - nivolumab
KW - PD-1
KW - platelet-to-lymphocyte ratio
KW - prognostic factor
UR - http://www.scopus.com/inward/record.url?scp=85131701727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131701727&partnerID=8YFLogxK
U2 - 10.2217/imt-2021-0207
DO - 10.2217/imt-2021-0207
M3 - Review article
C2 - 35465726
AN - SCOPUS:85131701727
SN - 1750-743X
VL - 14
SP - 709
EP - 725
JO - Immunotherapy
JF - Immunotherapy
IS - 9
ER -
